Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB095 and BIIB074 in Painful Diabetic Polyneuropathy
NCT04106050Phase 1Withdrawn
- Sponsor
- Biogen
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIIB-095 in diabetic polyneuropathy (DPN) (7 arms), sponsored by Biogen. Primary endpoint: Change in Nerve Excitability from Baseline at Day 8. Planned start Sep 2020; status: withdrawn.
02
Drugs
BIIB-095
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT04106050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106050.